SCHEMBL7491428

SCHEMBL7491428

CNC(=O)CC(C(=O)N(O)CCCc1ccc(Cl)cc1)C(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 1/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ HDAC10 Q969S8 1/20 0.40
▸ HDAC11 Q96DB2 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ HDAC9 Q9UKV0 1/20 0.40
▸ HDAC5 Q9UQL6 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ POLB P06746 3/20 0.38
▸ GAA P10253 2/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ FDPS P14324 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7488762 0.80 HRH3 (0.44) CYP1A2CYP2C19POLBFDPSKMT2A
SCHEMBL7493044 0.72 TACR1 (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7493051 0.72 ALDH1A1 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6847096 0.70 HDAC1 (0.65) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9374769 0.68 CYP1A2 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7493128 0.67 EPHX2 (0.40) FDPSLMNAALOX5RAB9AKCNH2
SCHEMBL6241724 0.67 CYP1A2 (0.57) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7493136 0.66 ALDH1A1 (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL12418966 0.65 PPARA (0.45) FDPSALOX5ALDH1A1PPARGPPARA
SCHEMBL8142471 0.64 SLC6A4 (0.57) POLBKMT2ASLC6A4SLC6A3FFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6462042-B1 TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITORS; INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, CANCER, CARDIO-VASCULAR DISEASES, RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPOROSIS, NEURODEGENERATION, ALZHEIMER'S DISEASE, STROKE DARWIN DISCOVERY LIMITED (GB) 2002-10-08 — — US claimed
EP-1237867-A1 HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS Darwin Discovery Limited (GB) 2002-09-11 — — EP claimed
WO-2001044188-A1 HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS DARWIN DISCOVERY LIMITED (GB) 2001-06-21 — — WO claimed
US-6462042-B1 TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITORS; INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, CANCER, CARDIO-VASCULAR DISEASES, RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPOROSIS, NEURODEGENERATION, ALZHEIMER'S DISEASE, STROKE DARWIN DISCOVERY LIMITED (GB) 2002-10-08 — — US disclosed
Send feedback